Apellis Pharmaceuticals Inc logo

APLS

Apellis Pharmaceuticals Inc

$65.76

Earnings Summary

Revenue
$14.38Mn
Net Profits
$-138.94Mn
Net Profit Margins
-966.1%

Highlights

Revenue:

Apellis Pharmaceuticals Inc’s revenue jumped +Inf% since last year same period to $14.38Mn in the Q1 2022. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -76.15% fall in its revenue since last 3-months.

Net Profits:

Apellis Pharmaceuticals Inc’s net profit jumped 24.35% since last year same period to $-138.94Mn in the Q1 2022. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated 6.08% jump in its net profits since last 3-months.

Net Profit Margins:

Apellis Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -966.1% in the Q1 2022. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -293.73% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Apellis Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.36
EPS Estimate Current Year
-1.36

Highlights

EPS Estimate Current Quarter:

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -1.36 - a -3.03% fall from last quarter’s estimates.

EPS Estimate Current Year:

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -1.36.

Key Ratios

Key ratios of the Apellis Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.42
Return on Assets (ROA)
-0.36
Return on Equity (ROE)
-6.62
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 38.79% since last year same period to -1.42 in the Q1 2022. This indicates that the Apellis Pharmaceuticals Inc has generated 38.79% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Apellis Pharmaceuticals Inc’s return on assets (ROA) stands at -0.36.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Apellis Pharmaceuticals Inc’s return on equity (ROE) stands at -6.62.

Dividend Per Share (DPS):

Apellis Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-1.32
-1.42
-7.58%

Company Information

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Organisation
Apellis Pharmaceuticals Inc
Headquarters
Waltham, Massachusetts, United States
Employees
374
Industry
Distribution Services
CEO
Cedric Francois